Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21705312 | 0.85 | ATM (0.38) | KMT2AALDH1A1HPGDATM | |
| SCHEMBL4180752 | 0.85 | PIK3CD (0.53) | KMT2APIK3CDGAAATM | |
| SCHEMBL4182889 | 0.81 | ALDH1A1 (0.42) | KMT2APIK3CDERN1ALDH1A1GLA | |
| SCHEMBL4069722 | 0.78 | ALDH1A1 (0.55) | KMT2AALDH1A1GAACYP1A2CYP3A4 | |
| SCHEMBL4181249 | 0.74 | ATM (0.56) | PIK3CDALDH1A1ATM | |
| SCHEMBL4167601 | 0.71 | ELANE (0.39) | KMT2APIK3CDERN1ALDH1A1CYP1A2 | |
| SCHEMBL4174565 | 0.71 | ALDH1A1 (0.44) | KMT2AALDH1A1GLAGAAGRM2 | |
| SCHEMBL4178020 | 0.71 | CCR1 (0.39) | KMT2APIK3CDALDH1A1GAAATM | |
| SCHEMBL4182705 | 0.70 | ATM (0.55) | KMT2APIK3CDALDH1A1GAAATM | |
| SCHEMBL1597913 | 0.70 | ATM (0.51) | KMT2APIK3CDERN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | KMT2A 829/4885PIK3CD 16/4885ERN1 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.